Cetuximab is the single targeted therapy approved for the treatment of head and neck cancer (HNSCC). Predictive biomarkers have not been established and patient stratification based on molecular tumor profiles has not been possible. Since EGFR pathway activation is pronounced in basal subtype, we hypothesized this activation could be a predictive signature for an EGFR directed treatment. From our patient-derived xenograft platform of HNSCC, 28 models were subjected to Affymetrix gene expression studies on HG U1331 2.0. Based on the expression of 821 genes, the subtype of each of the 28 models was determined by integrating gene expression profiles through centroid-clustering with previously published gene expression data by Keck et al. The models were treated in groups of 5-6 animals with docetaxel, cetuximab, everolimus, cis-or carboplatin and 5-fluorouracil. Response was evaluated by comparing tumor volume at treatment initiation and after 3 weeks of treatment (RTV). Tumors distributed over the 3 signature-defined subtypes: 5 mesenchymal/inflamed phenotype (MS), 15 basal type (BA), 8 classical type (CL). Cluster analysis revealed a strong correlation between response to cetuximab and the basal subtype. RTV MS 3.32 vs. BA 0.78 (MS vs. BA, unpaired t-test, p 0.0002). Cetuximab responders were distributed as following: 1/5 in MS, 5/8 in CL and 13/15 in the BA group. Activity of classical chemotherapies did not differ between the subtypes. In conclusion basal subtype was associated with response to EGFR directed therapy in head and neck squamous cell cancer patient-derived xenografts.
Introduction
Head and neck cancer comprises a heterogeneous group of tumors arising from the upper aero digestive tract. The most common histology of tumors arising in the oral cavity, oropharynx, hypopharynx and larynx is squamous cell carcinoma (HNSCC). Despite recent advances in the diagnosis and treatment, especially the metastatic and recurrent setting remains a major challenge with fatal outcome for most patients within a few months after diagnosis. Within the last years the molecular understanding of HNSCC has increased tremendously. Especially large multi-center, national or even international efforts, such as the cancer genome atlas project led to a deeper understanding of the heterogeneous landscape of molecular aberrations found within this disease. [1] [2] [3] In addition, gene expression analyses have proven to be a useful tool for classification of tumors. For breast cancer such tools have arrived in the clinical routine for the evaluation of the risk of recurrence and thereby influence the decision for adjuvant chemotherapy. 4, 5 Several groups have independently defined molecular subtypes of HNSCC based on gene expression profiles. [6] [7] [8] [9] All groups defined a basal-like subtype which is characterized by high expression of epidermal growth factor receptor (EGFR) pathway members, and a classical subtype, which is defined by high expression of cell cycle genes and genes associated with xenobiotic exposure. Furthermore, mesenchymal and atypical subtypes have been defined, whereas some authors combined the latter two in one subgroup. The different molecular subtypes have been associated with a variety of clinical and biological characteristics such as histological appearance, lymph node metastasis, HPV status and patient survival. 6, 8, 10, 11 Unfortunately, the gain of knowledge and understanding of the underlying biology in HNSCC has not led to defining novel biomarkers or changed clinical practice yet. Treatment decision in clinical routine remains based on conventional factors such as tumor stage, patient performance, comorbidities and patient wish. To date, cetuximab, a monoclonal antibody directed against the extracellular domain of EGFR is the only approved targeted treatment for HNSCC. EGFR protein expression evaluated by immunohistochemistry and gene amplification was not found predictive for EGFR targeted treatment. 12, 13 Currently, no clinically validated biomarker exists, which would allow treatment stratification. It has been questioned whether HPV-positive tumors respond to EGFR directed treatment not least because adequate preclinical models are scarce and translational studies on patient-derived material have the difficulty that patients are rarely treated with a single agent to define a particular biomarker next to the challenge of appropriate tissue availability.
14 Patient-derived xenografts (PDX) have been defined as preclinical models, reflecting patient tumors very closely. Therefore, they are accepted as suitable models for biomarker studies and compound evaluation. [15] [16] [17] To further engage into biomarker research our panel of head and neck PDX was evaluated for whole gene expression as well as mutational patterns. Based on previous work, 6 we hypothesized that the basal subtype gene expression signature of HNSCC could be predictive for cetuximab response, due to the activation of the EGFR pathway axis.
Materials and Methods

PDX generation, treatment and evaluation of response
All patients included in our study had given written informed consent. 
Patient survival analysis with regard to engraftment
Follow-up data from patients enclosed in the study were collected retrospectively. Excluded were patients whose tumors grew out as lymphoma in mice (N 5 22) and patients with incomplete follow-up data (N 5 17). Overall survival was defined as time from tumor resection to death or the date of the last contact. Engraftment in mice was stated, if stable growth of tumors was observed after 2nd passage Multivariate cox regression analysis was used to calculate established prognostic factors. For Cox regression and Kaplan-Meier survival analysis SPSS version 21 was used. Due to missing results from drug testing, two models were not eligible for analysis.
Mutational analysis and integration
Tumors grown as xenograft models were subjected to Next Generation Sequencing (NGS) analysis as described previously.
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What's new? Head and neck squamous cell carcinoma (HNSCC) has multiple subtypes, including basal and classical subtypes, which exhibit elevated expression of epidermal growth factor receptor (EGFR) pathway members. EGFR inhibition is the central action of cetuximab, the only targeted treatment approved for HNSCC. Whether EGFR expression predicts cetuximab response, however, is unclear. In our study, analysis of whole gene expression in patient-derived xenografts revealed a positive association between the basal subtype of HNSCC and cetuximab response. By contrast, mesenchymal subtype tumors were associated with cetuximab resistance. Functional analyses revealed an enrichment in EGFR pathway gene expression in the basal subtype.
Mutational load was evaluated by comparing the number of variant calls excluding annotated germline polymorphisms as indexed at dbSNP NCBI database. Mutations in TP53 and PI3KCA genes were analyzed for enrichment in different molecular subtypes, since these genes were frequently altered in our PDX HNSCC panel.
mRNA expression analysis
Tumor RNA of PDX-derived tumors from the untreated control group was extracted from each sample using Qiagen RNeasy Kit according to the manufacturer's protocol. The integrity of RNA was determined using the Agilent 2100 Bioanalyzer. Total RNA were assayed using Affymetrix HG U1331 2.0 microarrays evaluating >47,000 transcripts. Quality control procedures were applied to probe level intensity files. Raw data were deposited with accession number GSE84713 on GEO repository (http://www.ncbi.nlm.nih.gov/geo/). The R-package "affyPLM" 18 was used to background-correct CEL files with the GC-RMA 19 algorithm. Initial quality analyses included PCA-clustering of raw-data, analysis of mRNAdegradation and MA-Plot outlier-detection. Next, expression data were quantile-normalized and the R-package "LIMMA" 20 was applied for linear differential expression analysis. Differential expression p-values and Q-values were defined significant when they were lower than 0.05. The p-values were corrected for multiple testing by applying a Benjamini and Hochberg 21 correction to obtain Q-values. The significant absolute log foldchange was set to one. For gene-set enrichment analysis, we used the Broad Institute R-Package "GSEA" 22 with MSigDB 23 signature file "c2.all.v5.1.symbols.gmt."
Centroid cluster analysis
Sample subtypes were determined by identifying the reference subtype-clusters to which they were most significantly similar, where reference-clusters of the subtypes were represented as their centroids, i.e. scaled characteristic subsets of genes. A sample was defined as being significantly similar to a subtype-centroid if the Q-value of the Pearsoncorrelation p-values was lower than 0.05, as shown in Supplementary 
Results
PDX platform
As described previously, we generated a large HNSCC xenograft platform for compound evaluation and biomarker research. By collecting follow-up data for 62 patients, who were diagnosed and treated at the Charit e University hospital and enclosed in the study, we here investigated the prognostic value of the tumor engraftment. Patient characteristics are shown in Supplementary Table S2 . Groups were balanced in regard to engraftment: n 5 30 engrafted and n 5 32 no engrafted. Survival analysis revealed a trend to a higher probability of death, if tumors did growth on mice with a hazard ratio of 2.007, (95% CI: 0.967-4.165); Rank (Mantel-Cox) p 5 0.053 (Fig. 1) ; furthermore, average overall survival for patients whose tumors engrafted was 21.1 months (95% CI: 16.6-25.7) whereas patients whose tumor did not grow on mice had an average overall survival of 28.4 (95% CI: 23.4-33.4) months. Interestingly, traditional prognostic factors of HNSCC such as tumor stage, differentiation, gender, age and site of tumor origin did not influence overall survival in our cohort.
Gene expression -class definition
Twenty-eight PDX of head and neck cancer were evaluated for whole gene expression (detailed clinical information of the 28 models are summarized in Supplementary Table S3) . Applying the subtype definition described by Keck et al. we were able to classify the 28 PDX models by gene expression values of 821 genes into the three major groups of basal (BA n 5 15), classical (CL n 5 8) and mesenchymal/inflamed (MS n 5 5) subtype. Most samples clustered in the basal subtype. The two HPV-positive models HN10309 and HN11303 were assigned to the classical and mesenchymal/inflamed subtype, respectively. 
Tumor Markers and Signatures
Klinghammer et al.
Since stroma associated genes expression change during the process of tumor engraftment in mice, we explored whether stroma associated genes influenced the class definition. We used results from Peng et al. who previously defined differently expressed genes between head and neck patient tumors and thereof derived PDX. 24 Sixty-five of these differently expressed genes between patient tumors and PDX were found in the set of 821, which defined the molecular subtype. In a second analysis, we repeated molecular subtyping after removing these 65 genes, which did not result in change of subtype assignment for any of the samples.
For visualization, a cluster heatmap was created showing the PDX samples' clustering-pattern based on their pair-wise correlation of the expression of the 821 signature-defining genes from Keck et al. Utilization of the expression of the 821-genes during the single-linkage clustering did not create a clustering-pattern that corresponded classification-subtypes although all p-values were significant. Causes may be due to low sample number in conjunction with the fact that the signature was trained on different samples and different technologies, thereby causing a low signature-to-signal ratio ( Supplementary  Fig. S1a ). We therefore increased the noise-to-signal ratio of the data by restricting the analysis to the 300 strongest classdefining genes i.e. above-noise genes with the result of a clear distinction of the three groups ( Supplementary Fig. S1b ). When re-classifying samples based on the 300 gene-signature, only a single sample (HN11143) changed its subtype from classical to mesenchymal, the remaining classifications stayed identical to the 821 gene-signature.
Functional analysis
We further evaluated functional pathway enrichment employing gene set enrichment analysis (GSEA) between the three major subtypes. As expected, the EGFR pathway was positively enriched within the basal subtype (enrichment score 0.75, p 5 0.01). Gene expression values differed between the basal and mesenchymal subtypes significantly especially for EREG, AREG, EGFR, NRG1 and HBEGF.
Furthermore, the enrichment plot revealed a positive correlation of well-differentiated tumors with a basal subtype (enrichment score 0.72, p 5 0.02) in comparison to mesenchymal subtype which showed a negative enrichment as shown in Figures 2 and 3 .
Correlation of subtypes with response to treatment in head and neck PDX All 28 PDX models with complete datasets for response to single-agent treatment with either docetaxel, carbo-or cisplatin, 5-fluorouracil, cetuximab or everolimus were evaluated for correlation of the subtype with the response to treatment. Whereas responses to docetaxel, platinum compounds, everolimus or 5-fluorouracil were not enriched in any particular subtype as shown in Supplementary Figure S2 . However, there was a significant enrichment of cetuximab responders within the basal subtype. In contrast, models classified as mesenchymal/inflamed subtype were less likely to respond to cetuximab (unpaired t-test BA vs. MS p 5 0.0002) as shown in Figure 4 .
Mutational profiles
We further analyzed whether common mutations in head and neck cancer can be found predominantly in one of the subgroups and whether the mutational profile was correlated with response in xenograft models. The median number of mutations identified by panel sequencing (Illumina Cancer panel) of our models was 42,6 per sample. Within the different subtypes no significant differences were observed with regard to mutational load (BA 42.7 vs. CL 44.5 vs. MS 40). TP53 and PI3KCA were the most frequently altered genes found in our cohort. While the frequency of TP53 mutation was equally distributed across different subtypes, we observed a clear enrichment of PI3KCA mutation in MS subtypes. The percentages of mutated PI3KCA samples within the subgroups were BA 13.3% vs. CL 16.6% vs. MS 60%. However, no association of response and mutational status of TP53 or PI3KCA to any of the evaluated compounds was observed.
Discussion
Cetuximab is the only targeted agent approved for the treatment of head and neck cancer and so far no predictive biomarker has been identified and clinically validated. In our study, we reported a significant association between the response to cetuximab and the molecular subtype evaluated by gene expression in HNSCC PDX. By assigning molecular subtypes in 28 HNSCC PDX, we were able to show that basal subtype was associated with response to cetuximab. In contrast, the mesenchymal subtype was associated neither with growth delay nor with tumor regression when treated with cetuximab. Bossi et al. recently showed that patients with a long progression-free survival under cetuximab maintenance therapy can be predominantly found in the basal subtype group. 25 This is very much in line with our findings and supports the notion of prospective evaluation of gene expression profiles in regard to patient stratification. Based on our preclinical data the positive and negative predictive value of basal subtype to predict cetuximab response was 68% and 77%, respectively, whereas the negative predictive value for mesenchymal subtype reached 94%. Chung et al. were the first that proposed four molecular subtypes evaluating 60 head and neck tumor gene expression profiles and showed that patients within the group with EGFR activation had the worst prognosis. 6 Therefore, the hypothesis that tumors with EGFR activation might derive a major benefit from EGFR antibody treatment was raised but remained a major challenge to prove, since the group also showed that available cell lines for preclinical evaluation did Tumor Markers and Signatures not cluster within patient expression profiles. Furthermore, in the clinical setting patients were usually not treated with single agent cetuximab rather than combined treatment. Within our work we reported functional pathway analysis that revealed a high expression of genes found in the EGFR pathway especially in the basal subtype. Gene expression of AREG and EREG, which are ligands to the EGFR, have previously been associated with cetuximab response in colorectal cancer. 26 Beside the clustering analysis algorithm developed by Keck et al. which we employed for our work, De Cecco et al. independently also suggested a subtype clustering model for head and neck cancer. 7, 10 For comparative analysis, we evaluated the distribution of our PDX models over the six subtypes defined by De Cecco and co-workers. This did not result in a significant mapping for almost 50% of our PDX models. We therefore restricted our analysis to the classification developed by Keck et al. However, both groups defined a classical subtype with similar phenotype. By evaluating cell line response data for rapamycin De Cecco hypothesized the classical subtype (Cl5) might respond to mTOR inhibitor treatment. We could not confirm this hypothesis in our PDX models: Tumors responding to treatment with the mTOR inhibitor everolimus and non-responders did not cluster to different subtypes.
Next to histological appearance, genetic profile and protein expression it has been shown by several groups that gene expression patterns of patient tumors are mirrored in PDX. 15, [27] [28] [29] Therefore, PDX are considered as models that resemble the primary tumors. However, some restrictions remain: Especially tumors with a clinically aggressive behavior resulted in stable growth in mice. So far no predictive marker of successful engraftment in mice has been identified for HNSCC. By following up patient survival, we were able to show that successful tumor engraftment in mice is associated with a poorer prognosis. Traditional prognostic factors for patients with head and neck cancer such as TNM were not mirrored in our cohort, which might be due to tumor selection at operation toward large, high T-stage carcinomas during the process of establishment. We therefore have to be aware of selecting for this unfavorable yet clinically important patient cohort and our findings might not be applicable to all patients. Furthermore, within this work we evaluated only a limited number of PDX. Taking into consideration the differences of PDX and human tumors the findings reported are indicative and cannot be applied to patients without further evaluation in a clinical setting. However, with the previous reports from other groups, our work adds further evidence of the predictive value of gene expression signature for cetuximab treatment, creating a rationale for evaluation in a patient cohort. In addition, future research regarding the functional differences of the subtypes is motivated by the findings of this work.
